Anlotinib treatment of papillary thyroid carcinoma via inhibition of EGFR
Oncology Letters · 20.11.2026 · 33 (1) · 1-11
DOI: 10.3892/ol.2026.15962 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Letters, online erschienen am 20.11.2026. Verfasst von Min Zhang und 12 weiteren Autor:innen.
Abstract (Originalsprache)
The present study explored the therapeutic effect and molecular mechanisms of anlotinib in a model of papillary thyroid carcinoma (PTC) with BRAF V600E and telomerase reverse transcriptase promoter cooccurring mutations, providing a theoretical basis for identifying biomarkers for predicting the effectiveness of anlotinib treatment in radioactive iodine refractory‑PTC. The human PTC MDA‑T32 cell line was cultured in vitro and treated with anlotinib. The effects of anlotinib on the proliferation, migration, apoptosis and cell cycle of MDA‑T32 cells were observed using CCK‑8 assay, wound‑healing assay and flow cytometry. In addition, the tumor volume and body weight of subcutaneous tumorigenic model BALB/c‑nu mice were recorded after 14 days of anlotinib treatment. Histopathological staining and immunohistochemical staining for Ki‑67 and CD31 were performed on the tumor tissues of the mice. The tumor tissues were also subjected to protein and phosphorylomics sequencing. Western blotting was conducted to detect the protein expression of phosphorylated (p‑)EGFR, phosphorylated‑heat shock protein 90 α family class B member 1 (p‑HSP90AB1), phosphorylated‑eukaryotic elongation factor 2 (p‑eEF2), eEF2, cellular proto‑oncogene tyrosine‑protein kinase Src (c‑SRC), JAK2 and STAT3 in the tumor tissues. Anlotinib inhibited the growth of MDA‑T32 cells in a dose‑ and time‑dependent manner. The drug also significantly reduced the migratory and colony formation ability of the MDA‑T32 cells. Anlotinib also induced apoptosis and caused G2/M phase arrest in the MDA‑T32 cells. In addition, it effectively suppressed the growth of subcutaneous transplanted tumors in mice. Immunohistochemical staining for Ki‑67 and CD31 demonstrated that anlotinib significantly inhibited tumor cell proliferation and angiogenesis. Furthermore, compared with the control, anlotinib downregulated the protein expression of p‑EGFR, p‑HSP90AB1, p‑eEF2, eukaryotic elongation factor 2 (eEF2), c‑SRC, JAK2 and STAT3 in mouse tumor tissues. In conclusion, anlotinib may suppress EGFR and the downstream c‑SRC/JAK/STAT3 signaling pathway through the concomitant inhibition of HSP90AB1 and eEF2K in a PTC model. However, the precise causal associations between these pathway components require further mechanistic validation.
Zitieren
APA
Zhang, M., Meng, M., Zhao, S., Long, W., Liu, C., Chen, R., Meng, Q., Lin, Z., Yang, T., Huang, H., Liu, B., Wang, X., & Su, Y. (2026). Anlotinib treatment of papillary thyroid carcinoma via inhibition of EGFR. Oncology Letters, 33(1), 1-11. https://doi.org/10.3892/ol.2026.15962
Vancouver
Zhang M, Meng M, Zhao S, Long W, Liu C, Chen R, et al. Anlotinib treatment of papillary thyroid carcinoma via inhibition of EGFR. Oncology Letters. 2026;33(1):1-11. doi:10.3892/ol.2026.15962
BibTeX
@article{Zhang2026,
author = {Zhang, Min and Meng, Mingyao and Zhao, Shunshun and Long, Wei and Liu, Chuanyuan and Chen, Ruochuan and Meng, Qiuyu and Lin, Zhuying and Yang, Tingting and Huang, Haohan and Liu, Bin and Wang, Xiaodan and Su, Yanjun},
title = {Anlotinib treatment of papillary thyroid carcinoma via inhibition of EGFR},
journal = {Oncology Letters},
year = {2026},
volume = {33},
number = {1},
pages = {1--11},
doi = {10.3892/ol.2026.15962}
}
EUVIMED